A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE)

Abstract

Hereditary angioedema (HAE) due to C1 esterase inhibitor (C1-INH) deficiency (HAE-C1-INH) is a rare but medically significant disease that can be associated with considerable morbidity and mortality. Research into the pathogenesis of HAE-C1-INH has expanded greatly in the last six decades and has led to new clinical trials with novel therapeutic agents and treatment strategies. Mechanisms of pharmacotherapy include (a) supplementing C1-INH, the missing serine-protease inhibitor in HAE; (b) inhibiting the activation of the contact system and the uncontrolled release of proteases in the kallikrein-kinin system, by blocking the production/function of its components; (c) inhibiting the fibrinolytic system by blocking the production/function of its components; and (d) inhibiting the function of bradykinin at the endothelial level. Strategies for managing HAE-C1-INH are aimed at treating acute attacks, or preventing attacks, through the use of prophylactic treatment. Available agents for treating acute attacks include plasma-derived C1-INH concentrates, a recombinant C1-INH, a bradykinin B2 receptor antagonist, and a plasma kallikrein inhibitor. Long-term prophylactic treatments include attenuated androgens, plasma-derived C1-INH concentrates, and anti-fibrinolytics. Plasma-derived C1-INH and a bradykinin B2 receptor antagonist are already approved for self-administration at home. The number of management options for HAE-C1-INH has increased considerably within the past decade, thus helping to alleviate the burden of this rare disease.

This is a preview of subscription content, log in to check access.

Fig. 1

References

  1. 1.

    Bork K, Hardt J, Witzke G (2012) Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 130:692–697

    Article  PubMed  Google Scholar 

  2. 2.

    Bork K, Maurer M, Bas M et al. (2011) German guidelines for hereditary angioedema due to C1-INH deficiency. Mainz: German Society for Angioedema Research. Available in English at www.angioedema.de/englisch/infos.htm. Accessed 21 Dec 2015

  3. 3.

    Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B (2012) Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 67:147–157

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Craig T, Aygoren-Pursun E, Bork K, Bowen T, Boysen H, Farkas H, Grumach A, Katelaris CH, Lockey R, Longhurst H et al (2012) WAO guideline for the management of hereditary angioedema. World Allergy Organ J 5:182–199

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Gandhi PK, Gentry WM, Bottorff MB (2012) Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 32:902–909

    Article  PubMed  Google Scholar 

  6. 6.

    Bork K, Bygum A, Hardt J (2008) Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 100:153–161

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, Reshef A, Ritchie B, Moldovan D, Shirov T et al (2009) Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 124:801–808

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Bork K, Meng G, Staubach P, Hardt J (2005) Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45:1774–1784

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Farkas H, Jakab L, Temesszentandrasi G, Visy B, Harmat G, Fust G, Szeplaki G, Fekete B, Karadi I, Varga L (2007) Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 120:941–947

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Bork K, Staubach P, Hardt J (2008) Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 63:751–757

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Rizk C, Karsh J, Santucci S, Yang W (2013) Self-administration of intravenous C1 esterase inhibitor in hereditary angioedema. CMAJ 185:791–792

    Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Bork K (2014) Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Immunotherapy 6:533–551

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Bork K, Hardt J (2009) Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Med 122:780–783

    Article  PubMed  Google Scholar 

  14. 14.

    Kalfus I, Frank M (2010) C1 inhibitor therapy and hereditary angioedema. Am J Med 123:e15, Author reply e17

    Article  PubMed  Google Scholar 

  15. 15.

    Bork K, Hardt J (2011) Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 154:81–88

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Cinryze: European Public Assessment Report. London, UK (2011) European Medicines Authority. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001207/human_med_001448.jsp&mid=WC0b01ac058001d124 Accessed 21 Dec 2015

  17. 17.

    Lumry W, Manning ME, Hurewitz DS, Davis-Lorton M, Fitts D, Kalfus IN, Uknis ME (2013) Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr 162(1017–1022):e1011–e1012

    Google Scholar 

  18. 18.

    Tourangeau LM, Castaldo AJ, Davis DK, Koziol J, Christiansen SC, Zuraw BL (2012) Safety and efficacy of physician-supervised self-managed c1 inhibitor replacement therapy. Int Arch Allergy Immunol 157:417–424

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, Konig W, Knolle J et al (1991) Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102:769–773

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henk S, Breipohl G, Konig W, Knolle J et al (1991) Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 102:774–777

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Bork K, Yasothan U, Kirkpatrick P (2008) Icatibant. Nat Rev Drug Discov 7:801–802

    CAS  Article  Google Scholar 

  22. 22.

    Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W (2007) Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 119:1497–1503

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H et al (2010) Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532–541

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, Riedl M, Li H, Craig T, Bloom BJ et al (2011) Randomized placebo-controlled trial of the bradykinin B receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 107:529–537

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Maurer M, Aberer W, Bouillet L, Caballero T, Fabien V, Kanny G, Kaplan A, Longhurst H, Zanichelli A (2013) Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One 8:e53773

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A, Caballero T, Bloom B, Nair N, Malbran A (2014) Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy 69:305–314

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, Horn PT, Pullman WE (2010) Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 363:523–531

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, Pullman WE (2010) EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104:523–529

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Sheffer AL, MacGinnitie AJ, Campion M, Stolz LE, Pullman WE (2013) Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol 110:184–188.e182

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R (2013) Use of ecallantide in pediatric hereditary angioedema. Pediatrics 132:e490–e497

    Article  PubMed  Google Scholar 

  31. 31.

    Li HH, Campion M, Craig TJ, Soteres DF, Riedl M, Lumry WR, MacGinnitie AJ, Shea EP, Bernstein JA (2013) Analysis of hereditary angioedema attacks requiring a second dose of ecallantide. Ann Allergy Asthma Immunol 110:168–172

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, Haase G, Kaufman L, Hack CE (2010) Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 126:821–827.e814

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Riedl MA, Levy RJ, Suez D, Lockey RF, Baker JW, Relan A, Zuraw BL (2013) Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol 110:295–299

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Riedl MA, Bernstein JA, Li H, Reshef A, Lumry W, Moldovan D, Farkas H, Levy R, Baker J, Hardiman Y et al (2014) Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol 112:163–169.e161

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Sheffer AL, Austen KF, Rosen FS (1972) Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 287:452–454

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Fust G, Farkas H, Csuka D, Varga L, Bork K (2011) Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Investig 41:256–262

    CAS  Article  Google Scholar 

  37. 37.

    Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, Craig T, Grant JA, Hurewitz D, Bielory L et al (2010) Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 363:513–522

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Zuraw BL, Kalfus I (2012) Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 125:938.e931–937

    Article  Google Scholar 

  39. 39.

    Bernstein JA, Manning ME, Li H, White MV, Baker J, Lumry WR, Davis-Lorton MA, Jacobson KW, Gower RG, Broom C et al (2014) Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract 2:77–84.e71

    Article  PubMed  Google Scholar 

  40. 40.

    Bork K, Witzke G (1989) Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 83:677–682

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Martinez-Saguer I, Heller C, Fischer D, Ettingshausen CE, W. K (1999) Prophylactic treatment with pasteurised C1 inhibitor in hereditary angioedema (HAE)—a prospective 32 months follow up. Blood 94(10), Sup 1, Abstract # 1032:2339

  42. 42.

    Tallroth GA (2011) Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate. Int Arch Allergy Immunol 154:356–359

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Reshef A, Moldovan D, Obtulowicz K, Leibovich I, Mihaly E, Visscher S, Relan A (2013) Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy 68:118–124

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Martinez-Saguer I, Cicardi M, Suffritti C, Rusicke E, Aygoren-Pursun E, Stoll H, Rossmanith T, Feussner A, Kalina U, Kreuz W (2014) Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion 54:1552–1561

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Zuraw BL, Cicardi M, Longhurst HJ, Bernstein JA, Li HH, Magerl M, Martinez-Saguer I, Rehman SM, Staubach P, Feuersenger H et al (2015) Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy 70:1319–1328

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Spath PJ, Wuthrich B, Butler R (1984) Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema—evidence of a functionally critical level of C1-inhibitor concentration. Complement 1:147–159

    CAS  PubMed  Google Scholar 

  47. 47.

    Bhattacharjee G, Revenko AS, Crosby JR, May C, Gao D, Zhao C, Monia BP, MacLeod AR (2013) Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. Nucleic Acid Ther 23:175–187

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Konrad Bork.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bork, K. A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE). Clinic Rev Allerg Immunol 51, 183–192 (2016). https://doi.org/10.1007/s12016-016-8544-9

Download citation

Keywords

  • Hereditary angioedema
  • C1 inhibitor
  • C1-INH deficiency
  • Treatment for acute attacks
  • Prophylaxis